Clinical & Commercial Programs
AIVITA’s lead therapeutic focus is a patient-specific immunotherapy for the treatment of advanced cancers, currently being investigated in glioblastoma, melanoma, and ovarian cancer. To support these efforts, AIVITA has developed an anti-aging skin care technology currently available for sale to consumers. All proceeds from product sales support AIVITA’s cancer development pipeline. The company also has a preclinical program supported by grants using human stem cells differentiated into sheets of retinal tissue to treat degenerative retinal diseases.
Patient-specific dendritic cell, tumor cell immunotherapy for the treatment of glioblastoma, melanoma, and ovarian cancer.
Ovarian (Phase 2)
Glioblastoma (Phase 2)
Melanoma (Phase 1B)
Retinal Degeneration (Preclinical)